Description

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical firm dedicated to creating immune-modulating therapies, specifically targeting immuno-oncology and fibrotic conditions. The company's pipeline includes several key candidates: Lenabasum, an oral compound currently in Phase II trials, works by selectively engaging cannabinoid receptor type 2 (CB2) to address systemic lupus erythematosus. Corbus is also advancing CRB-601, an anti-integrin monoclonal antibody designed to combat cancer and fibrosis by inhibiting transforming growth factor ß (TGFß) activation. Furthermore, CRB-602, an anti-avß6/avß8 monoclonal antibody, aims to treat fibrotic diseases through its ability to block TGFß activation. Beyond these, Corbus is exploring a cannabinoid receptor type 1 inverse agonist program with broad therapeutic potential. This program targets various metabolic disorders like obesity, diabetic nephropathy and retinopathy, and nonalcoholic steatohepatitis. It also seeks to treat multiple fibrotic diseases, including those affecting the lung, heart, kidney, and liver, alongside other conditions such as ascites, cognitive impairments, Prader-Willi syndrome, and even smoking cessation. Corbus has a strategic licensing partnership with Jenrin Discovery, LLC. This collaboration focuses on the development and commercialization of a portfolio of licensed products, which encompasses Jenrin's extensive library of around 600 compounds, in addition to several existing and forthcoming patent protections. Established in 2009, the company operates from its headquarters in Norwood, Massachusetts.